Nootropic Peptides Compared: Semax vs Selank vs Dihexa vs P21 in Cognitive Research

# Nootropic Peptides Compared: Semax vs Selank vs Dihexa vs P21 in Cognitive Research

The search for effective nootropic peptides — compounds that enhance cognitive function through neurochemical mechanisms — has led researchers to a handful of exceptionally well-studied candidates. Among the dozens of peptides examined for their effects on memory, focus, neuroprotection, and neuroplasticity, four compounds have emerged as the most relevant tools for cognitive peptides research: Semax, Selank, Dihexa, and P21 (P021).

Researchers asking "what are the best peptides for brain research?" consistently encounter these four, and for good reason: they represent four mechanistically distinct approaches to brain enhancement, span a broad range of cognitive targets, and have accumulated meaningful evidence bases in preclinical models.

This comparative analysis examines each compound's mechanism, the current evidence for cognitive effects, and practical administration considerations — designed for researchers selecting tools for studies in memory, neuroprotection, neuroplasticity, or anxiety-modulated cognition.

> Research Use Only (RUO): All compounds discussed in this article are research chemicals intended for laboratory investigation. None of the information presented constitutes medical advice or recommendations for use outside of controlled research settings.

Why Compare These Four Nootropic Peptides?

These four peptides were selected for comparison because they represent four fundamentally different approaches to cognitive enhancement and neuroprotection in research:

• •Semax — Neurotrophic factor upregulation (BDNF/NGF pathway)
• •Selank — GABAergic modulation and enkephalin system interaction
• •Dihexa — HGF/c-Met receptor system potentiation and synaptogenesis
• •P21 — CNTF-derived BDNF enhancement via LIF signaling inhibition

Together, they span the major mechanistic categories currently under investigation in neuroprotection research. Understanding how they compare — and where they diverge — is essential for researchers designing experiments in synaptic plasticity, neurodegeneration, neurogenesis, and cognitive function.

Semax: The ACTH-Derived Neurotrophic Modulator

Structure and Origin

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of the adrenocorticotropin hormone fragment ACTH(4-10). Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax was designed to retain the neurotrophic properties of the ACTH fragment while eliminating hormonal (steroidogenic) activity (Dolotov et al., 2003).

The C-terminal Pro-Gly-Pro tripeptide extension enhances metabolic stability and provides additional biological activity, as PGP itself possesses immunomodulatory properties.

Mechanism of Action

Semax's primary mechanism involves the robust upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression across multiple brain regions. Research by Karpenko et al. (2006) demonstrated that Semax regulates both BDNF and its high-affinity receptor TrkB in the hippocampus, suggesting a coordinated enhancement of neurotrophic signaling (Karpenko et al., 2006).

Temporal dynamics studies have revealed that Semax produces region-specific and time-dependent effects on neurotrophin gene expression. In the hippocampus, BDNF mRNA increases are detectable within 20 minutes of administration and persist for up to 24 hours, while frontal cortex responses follow different kinetic profiles (Shadrina et al., 2010).

Key Research Findings

Neuroprotection in ischemia models: Genome-wide transcriptional analysis has shown that Semax affects the expression of genes related to immune and vascular systems during focal cerebral ischemia in rat models. The peptide modulates immunoglobulin gene expression and cytokine signaling pathways, suggesting a multi-target neuroprotective mechanism that extends beyond simple neurotrophic factor upregulation (Medvedeva et al., 2014).

Protein expression profiling: More recent work has confirmed Semax's protective effects at the protein level, demonstrating upregulation of active CREB (cAMP response element-binding protein) in subcortical structures following ischemia, while simultaneously downregulating pro-inflammatory and apoptotic markers MMP-9, c-Fos, and active JNK (Dmitrieva et al., 2021).

Neurotrophin receptor activation: Semax activates the transcription of neurotrophins and their receptors (TrkA, TrkB, TrkC) after cerebral ischemia, indicating it does not merely increase ligand availability but enhances the entire neurotrophic signaling infrastructure (Filippenkov et al., 2024).

Strengths for Research

• •Well-characterized BDNF/NGF upregulation kinetics
• •Extensive transcriptomic and proteomic data
• •Broad neurotrophic effect spanning multiple brain regions
• •Ischemia/neuroprotection models are well-established

Selank: The Tuftsin-Derived Anxiolytic Peptide

Structure and Origin

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide based on the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended with a C-terminal Pro-Gly-Pro sequence for enhanced stability. Like Semax, it was developed at the Institute of Molecular Genetics in Moscow, but its research profile skews toward anxiolytic and stress-modulatory effects rather than direct neurotrophic activity.

Mechanism of Action

Selank's mechanism is notably different from Semax and involves at least three distinct pathways:

1. GABAergic gene modulation: Research by Volkova et al. (2016) demonstrated that Selank administration affects the expression of multiple genes involved in GABAergic neurotransmission in the rat frontal cortex, including GABA receptor subunit genes (Gabra6, Gabrb1, Gabrb3, Gabre, Gabrq) and GABA transporter genes (Slc6a1, Slc6a11) (Volkova et al., 2016).

Interestingly, subsequent in vitro studies using IMR-32 neuroblastoma cells showed that Selank does not directly alter GABAergic gene expression in isolated neuronal cells, suggesting its effects require the intact neural circuit context and may be mediated indirectly through network-level interactions (Volkova et al., 2017).

2. Enkephalin system modulation: Selank dose-dependently inhibits enkephalin-degrading enzymes in plasma (IC50 ~15 μM), which may contribute to its anxiolytic properties by extending the half-life of endogenous enkephalins (Zozulya et al., 2001).

3. Serotonergic influences: Selank has been observed to modulate serotonin metabolism, contributing to its broader neurochemical profile that bridges anxiolysis and immunomodulation.

Key Research Findings

Anxiolytic efficacy investigations: A randomized controlled study evaluated Selank in the context of generalized anxiety disorders and neurasthenia, finding that investigated subjects had decreased baseline enkephalin levels that correlated with symptom severity. Changes in this parameter during the investigation period showed positive correlations with anxiety measurements (Zozulya et al., 2008).

Morphine withdrawal attenuation: Selank has shown capacity to attenuate aversive signs in a naloxone-precipitated morphine withdrawal model in rats, reducing the total withdrawal syndrome index by 39.6% at anxiolytic-relevant concentrations (Leontiev et al., 2022).

Immunomodulatory crossover: Unlike purely cognitive peptides, Selank bridges neuroimmunology — its tuftsin backbone confers immunomodulatory properties that interact with its anxiolytic mechanisms, making it a uniquely dual-function research tool.

Strengths for Research

• •Distinct GABAergic modulation profile
• •Dual anxiolytic-immunomodulatory activity
• •Enkephalin system interaction provides unique research angles
• •Useful for stress response and emotional regulation paradigms

Dihexa: The HGF/c-Met Synaptogenesis Agent

Structure and Origin

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide; developmental code PNB-0408) is an oligopeptide derived from angiotensin IV, developed at Washington State University by the laboratory of Dr. Joseph Harding. It was designed through systematic chemical modifications to create a stable, brain-penetrant compound that could potentiate hepatocyte growth factor (HGF) signaling at the c-Met receptor.

Mechanism of Action

Dihexa operates through a fundamentally different mechanism than Semax or Selank. Rather than modulating classical neurotransmitter systems or neurotrophins like BDNF, Dihexa targets the HGF/c-Met receptor pathway:

• •HGF binding and dimerization: Dihexa binds with high affinity to HGF, inducing its dimerization and facilitating c-Met phosphorylation in the presence of subthreshold concentrations of HGF. It effectively amplifies endogenous HGF signaling rather than acting as a direct receptor agonist.
• •Synaptogenesis and spinogenesis: Through c-Met activation, Dihexa promotes hippocampal dendritic spine formation and new synapse creation — structural changes that underlie learning and memory at the cellular level.

Key Research Findings

Cognitive rescue in neurodegenerative models: A 2021 study in APP/PS1 transgenic mice demonstrated that Dihexa restored spatial learning and cognitive functions in the Morris water maze test, increased neuronal cells and synaptophysin (SYP) expression, and activated the PI3K/AKT signaling pathway (Wang et al., 2021).

HGF/c-Met system review: A comprehensive review by Benoist et al. positioned the brain HGF/c-Met receptor system as a target for neurodegeneration research, noting that this growth factor system induces dendritic arborization and synaptogenesis when stimulated by Dihexa and related angiotensin-based analogs (Benoist et al., 2015).

Important note on research integrity: Researchers should be aware that the original 2014 pharmacological characterization paper by Benoist et al. in the Journal of Pharmacology and Experimental Therapeutics was retracted in April 2025. While subsequent independent studies (e.g., Wang et al., 2021) have continued to demonstrate Dihexa's effects through the PI3K/AKT pathway, the retraction of a foundational paper necessitates careful evaluation of the evidence base when designing new experiments. This does not invalidate all Dihexa research, but investigators should weight their experimental designs accordingly.

Strengths for Research

• •Unique HGF/c-Met mechanism distinct from neurotrophin pathways
• •Demonstrated structural synaptogenesis (not just functional)
• •Oral bioavailability and blood-brain barrier penetrance in preclinical models
• •PI3K/AKT pathway involvement opens cross-disciplinary research applications

Limitations

• •Key foundational paper retracted (2025)
• •Smaller overall evidence base compared to Semax/Selank
• •HGF/c-Met pathway involvement raises questions about growth factor pathway over-stimulation in long-term studies
• •No human investigation data

P21 (P021): The CNTF-Derived Neurogenic Compound

Structure and Origin

P21 (also designated P021; sequence Ac-DGGLAG-NH2; MW 578.3) is a tetrapeptide derived from the biologically active region of human ciliary neurotrophic factor (CNTF) through epitope mapping. Developed by the laboratory of Dr. Khalid Iqbal at the New York State Institute for Basic Research in Developmental Disabilities, P021 was designed to capture CNTF's neurotrophic properties in a small, drug-like molecule.

Mechanism of Action

P21's mechanism involves a two-pronged approach:

1. LIF signaling inhibition: P021 inhibits leukemia inhibitory factor (LIF) signaling, which normally suppresses neurogenesis in the adult brain. By blocking this inhibitory pathway, P021 de-represses neurogenic programs.

2. BDNF upregulation: Through LIF pathway inhibition and downstream effects, P021 increases BDNF expression, activating the TrkB/PI3K/AKT/GSK3β signaling cascade. This pathway convergence is particularly relevant for neurodegeneration research because GSK3β is a key kinase involved in tau hyperphosphorylation.

Key Research Findings

Prevention of cognitive impairment: In a landmark 18-month study using 3xTg-AD triple-transgenic mice, P021 administered in diet beginning at 3 months of age (before any overt pathology) rescued neurogenesis deficits in the dentate gyrus, prevented dendritic and synaptic protein loss, and preserved cognitive function. Critically, P021 also reduced abnormal tau hyperphosphorylation at multiple sites and decreased amyloid-β levels (Baazaoui & Iqbal, 2017).

CDKL5 deficiency research: Recent research has expanded P021's applications beyond Alzheimer's models, demonstrating its capacity to enhance neurogenesis and synaptic plasticity through BDNF upregulation in both in vitro and in vivo models of CDKL5 deficiency disorder, a rare genetic neurodevelopmental condition (Fuchs et al., 2024).

Dual pathology targeting: P21's ability to simultaneously address neurogenesis deficits, tau pathology, and amyloid-β accumulation in preclinical models makes it unique among the four peptides compared here. While Semax and Selank primarily target functional neuroprotection, and Dihexa targets structural synaptogenesis, P21 addresses the underlying proteinopathies characteristic of neurodegenerative disease models.

Strengths for Research

• •Simultaneous neurogenesis, tau, and amyloid-β pathway modulation
• •Long-term dietary administration studies demonstrate sustained efficacy
• •Oral bioavailability (administered in diet in mouse studies)
• •Clean BDNF/TrkB/PI3K/AKT/GSK3β pathway characterization
• •Expanding applications beyond neurodegeneration (CDKL5 deficiency)

Head-to-Head Comparison

Mechanism Summary Table

Administration, Half-Life, and Research Dosing

Understanding the practical pharmacology of each peptide is essential for experimental design. Semax and Selank share a common administration challenge: as peptides, they are rapidly degraded in plasma (~1–2 minutes biological half-life for unmodified heptapeptides). Both compounds are routinely administered via intranasal route in preclinical research, which delivers them directly to the olfactory epithelium and cerebrospinal fluid, effectively bypassing first-pass metabolism and achieving brain exposure that outlasts plasma levels.

For detailed half-life pharmacokinetics across peptide classes, see the Peptide Half-Life Complete Reference Guide.

> Dosing calculator: Use the Research Peptide Dosing Calculator to convert preclinical mg/kg doses to volume calculations for your experimental protocol.

Cognitive Domain Targeting: Which Peptide for What?

Researchers selecting among these four nootropic peptides should match compound choice to the specific cognitive domain under investigation. The table below maps each peptide to its primary and secondary cognitive research applications based on the available preclinical literature:

Key: +++ Primary indication with strong evidence; ++ Secondary indication with moderate evidence; + Minor role or indirect effect; "Not characterized" = insufficient data

Semax vs Selank: The Most Common Comparison

The most frequently searched comparison among this group is semax vs selank, and understandably so — both are Russian-developed heptapeptides with the same Pro-Gly-Pro C-terminal extension, similar intranasal administration routes, and overlapping cognitive research applications. Their differences are, however, fundamental:

• •Semax targets neurotrophic factor production (BDNF, NGF) and excels in neuroprotection and direct memory enhancement paradigms. It's the better choice for ischemia models, BDNF pathway research, and acute cognitive studies.
• •Selank targets GABAergic and enkephalin systems, with its primary cognitive contribution coming through anxiety reduction that secondarily improves performance. It's the better choice for stress-cognition interaction research, anxiety disorder models, and neuroimmune studies.

These compounds are not substitutes — they address different mechanistic questions.

Evidence Quality Assessment

Semax has the broadest and most mature evidence base among the four peptides. Its effects on BDNF expression have been replicated across multiple independent laboratories, and genome-wide transcriptomic data provides systems-level understanding of its mechanisms. The ischemia neuroprotection literature is particularly robust.

Selank similarly benefits from extensive investigation, particularly from Russian research groups. Its dual anxiolytic-immunomodulatory profile is well-characterized, though the observation that its GABAergic effects require intact neural circuits (and are absent in isolated neuronal cell cultures) adds mechanistic complexity that warrants further investigation.

Dihexa has the most limited — and most complicated — evidence base. The 2025 retraction of a key characterization paper introduces uncertainty that researchers must weigh carefully. However, independent studies (particularly Wang et al., 2021) have continued to demonstrate cognitive effects through the PI3K/AKT pathway. The HGF/c-Met mechanism remains scientifically interesting but requires additional independent validation.

P21 occupies a middle ground in evidence volume but stands out for the quality and rigor of its long-term preclinical studies. The 18-month 3xTg-AD mouse study is among the most comprehensive peptide intervention trials in the Alzheimer's model literature. Its expansion into CDKL5 research demonstrates versatility.

Research Application Guide

For ischemia/stroke neuroprotection research: Semax is the most extensively validated tool, with transcriptomic, proteomic, and functional data across multiple ischemia models.

For stress response and anxiety-related paradigms: Selank provides unique access to the GABAergic-enkephalin-serotonergic interface, with anxiolytic effects that don't carry sedative or muscle-relaxant confounds.

For synaptogenesis and structural plasticity studies: Dihexa offers direct HGF/c-Met-mediated spine formation and synapse creation, though researchers should carefully evaluate the evidence base given the 2025 retraction.

For neurodegeneration and neurogenesis research: P21 is uniquely positioned to address multiple aspects of neurodegenerative pathology simultaneously, with the added advantage of dietary administration for long-term studies.

For combinatorial research: These peptides' non-overlapping mechanisms suggest potential for combinatorial studies. Semax (BDNF upregulation) + Selank (GABAergic modulation) represents a frequently studied pairing in Russian literature. P21 (neurogenesis/tau) + any of the others could address complementary aspects of neurodegeneration.

Research Safety Profiles

None of the four compounds discussed here have completed formal human safety trials, and all are classified as research chemicals for laboratory use only. The following summarizes what is known from preclinical literature:

Semax has the most extensive safety data, largely due to its clinical registration in Russia and Ukraine for ischemic stroke and optic nerve disease. Animal studies across a range of doses have not identified major adverse effects. The peptide is rapidly degraded and shows no accumulation. The Pro-Gly-Pro metabolite is itself biologically active but well-tolerated in rodent models.

Selank shares a similar safety profile to Semax in preclinical studies. Unlike benzodiazepines (which also modulate GABA), Selank does not produce sedation, muscle relaxation, or dependence-like effects at anxiolytic doses in animal models — an important distinction for research design. No major organ toxicity has been reported in rodent studies.

Dihexa has the most limited safety characterization, compounded by the retraction of foundational pharmacology data. Its HGF/c-Met agonist activity raises theoretical concerns about long-term growth factor pathway activation (particularly relevant for cell proliferation models), but no direct evidence of harm has been reported in published preclinical studies at the doses tested.

P21 has been studied in long-term (18-month) rodent studies via dietary administration without reported toxicity. Its highly selective mechanism (LIF pathway inhibition rather than broad cytokine modulation) is considered favorable from a safety standpoint in the literature.

> All research with these compounds should follow institutional IACUC or equivalent guidelines. None of this information should be interpreted as guidance for use in humans.

Emerging Research Directions

Cross-Pathway Convergence

One of the most exciting aspects of comparing these four peptides is identifying where their apparently distinct pathways converge. Both Semax and P21 ultimately converge on BDNF signaling, but through entirely different upstream mechanisms — Semax through direct transcriptional activation and P21 through LIF pathway de-repression. This convergence raises the question of whether combining both approaches produces additive or synergistic BDNF effects.

Translational Gaps

All four peptides remain in preclinical stages with no completed human investigation programs. The translational gap between rodent model efficacy and potential application remains the central challenge in this research domain. Key barriers include:

• •Blood-brain barrier penetrance validation in larger species
• •Dose-response characterization beyond rodent models
• •Long-term safety profiling across species
• •Biomarker development for non-invasive efficacy monitoring

Research Integrity Considerations

The 2025 retraction of the Benoist et al. Dihexa characterization paper highlights the importance of independent replication in peptide research. Researchers working with any of these compounds should prioritize multi-laboratory validation and pre-registration of study designs to strengthen the evidence base.

Conclusion

Semax, Selank, Dihexa, and P21 represent four distinct approaches to nootropic and neuroprotective research, each with unique mechanistic profiles and evidence bases. Semax excels in neurotrophic factor modulation with the broadest research support. Selank offers unparalleled access to the GABAergic-enkephalin interface. Dihexa provides a unique window into HGF/c-Met-mediated synaptogenesis, albeit with evidence base caveats. P21 uniquely bridges neurogenesis, tau pathology, and amyloid-β reduction.

For researchers, the choice among these cognitive peptides should be driven by the specific molecular pathway under investigation, the disease model being employed, and the quality of available evidence for each compound in the relevant experimental context. The non-overlapping nature of their mechanisms also opens significant opportunities for combinatorial studies that could illuminate how different neuroprotective pathways interact.

As the field matures, head-to-head comparative studies conducted under standardized conditions will be essential for establishing relative efficacy and delineating the specific contexts in which each peptide offers the greatest utility as a research tool.

---

References

1. Dolotov OV, et al. The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo. Dokl Biol Sci. 2003;391:292-295. PubMed

2. Karpenko EA, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PubMed

3. Shadrina M, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010;41(1):30-35. PubMed

4. Medvedeva EV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. PMC

5. Dmitrieva VG, et al. Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion. Int J Mol Sci. 2021;22(12):6179. PubMed

6. Filippenkov IB, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cells. 2024;13(8):659. PMC

7. Volkova A, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31. PMC

8. Volkova A, et al. GABA, Selank, and Olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Front Pharmacol. 2017;8:89. PubMed

9. Zozulya AA, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315-317. PubMed

10. Zozulya AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PubMed

11. Leontiev DS, et al. Selank, a peptide analog of tuftsin, attenuates aversive signs of morphine withdrawal in rats. Bull Exp Biol Med. 2022;174(1):58-62. PubMed

12. Benoist CC, et al. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer's disease. J Alzheimers Dis. 2015;45(4):985-1000. PubMed

13. Wang D, et al. AngIV-analog Dihexa rescues cognitive impairment and recovers memory in the APP/PS1 mouse via the PI3K/AKT signaling pathway. Brain Sci. 2021;11(11):1487. PubMed

14. Baazaoui N, Iqbal K. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther. 2017;9(1):45. PubMed

15. Fuchs C, et al. Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. J Neurodev Disord. 2024;16(1):65. PMC

This article is for research and educational purposes only. All peptides discussed are research chemicals for laboratory use. Always follow institutional guidelines and applicable regulations when working with research compounds.

---

---

Supplier Pricing: Semax, Selank, Dihexa Research Compounds 2026

Pricing from the Peptides.SO database for the four compounds discussed in this comparison:

Semax (cognitive/nootropic research):

Selank (anxiolytic/immunomodulatory research):

Dihexa (synaptogenic/HGF-receptor research):

> P21 (CNTF-derived) pricing varies by supplier format — compare live at the Peptides.SO compare page. All compounds are research use only.

---

Frequently Asked Questions

What is the fundamental mechanistic difference between Semax and Selank?

Semax and Selank share tuftsin-derived heritage but operate through distinct primary pathways. Semax (ACTH 4-7 Pro8-Gly9-Pro10) enhances BDNF and NGF expression — directly potentiating neurotrophin signaling — while also acting as a dopamine reuptake inhibitor, producing a stimulatory/activating research profile. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is primarily immunomodulatory via tuftsin receptor engagement, with anxiolytic properties attributed to GABAergic potentiation rather than monoamine modulation. This means: Semax research focuses on cognitive enhancement, neurogenesis, and neuroprotection; Selank research centers on anxiety-like behavior, immune modulation, and stress-resilience — overlapping in their tuftsin lineage but divergent in primary mechanism.

Why does Dihexa rank among the most potent pro-cognitive compounds in preclinical models despite limited research volume?

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an HGF/SF mimetic that binds and activates the c-Met receptor — a receptor tyrosine kinase responsible for dendritic branching, synaptogenesis, and LTP facilitation in hippocampal circuits. McCoy et al. (2013) demonstrated cognition improvements in rodents at 7-8 orders of magnitude lower concentrations than BDNF, the benchmark neurotrophic compound. This extraordinary potency-to-dose ratio makes Dihexa a high-value research tool despite limited human clinical data. The c-Met axis is a legitimate high-priority target in Alzheimer's and synaptopathy research, which drives sustained scientific interest.

How do P21 and Semax differ in their neurotrophin-targeting approach?

Semax upregulates endogenous BDNF and NGF production — an indirect mechanism affecting expression at the gene level. P21 (CNTF-derived heptapeptide DGGLFEQ) is a direct CNTF receptor agonist — bypassing the full-length CNTF molecule and its gp130/LIFRβ/CNTFRα complex signaling directly through Jak-STAT, MAPK, and PI3K pathways. P21 research examines neurogenesis, neurite outgrowth, and neuronal survival across CDKL5 deficiency and Alzheimer's models. The practical distinction: Semax modulates the BDNF/NGF neurotrophic axis broadly; P21 targets the CNTF receptor specifically — relevant to different disease models and mechanistic questions.

Can Semax and Selank be used in the same research protocol without mechanistic confounding?

This depends on the research question. Since Semax's primary action is via BDNF/NGF upregulation and dopamine reuptake inhibition, while Selank works through tuftsin/GABAergic/immune pathways, their mechanisms are largely non-overlapping. Co-administration in rodent models studying anxiety + cognitive function simultaneously would allow mechanistic attribution if one compound's primary pathway is blocked as a control. However, without pathway isolation controls (e.g., receptor antagonists), interpreting co-administration data as attributable to either compound specifically is challenging. For mechanistic research, sequential or isolated protocols with washout periods are standard.

What is the research timeline for Semax in Russian clinical literature vs Western preclinical data?

Semax has an unusually long human research history for a nootropic peptide — it has been registered as a pharmaceutical in Russia since 1994 for cerebrovascular conditions and brain ischemia. Russian clinical literature (often not indexed in PubMed) includes data from stroke, TBI, and cognitive impairment populations. Western research remains largely preclinical, with studies focused on animal cognition models and cell-based BDNF induction assays. This divergence creates an interesting epistemic situation: the compound has more human exposure data than most research peptides, but less of that data is accessible in Western-standard randomized controlled trial formats.

What imaging or biomarker endpoints are most useful for preclinical research with these compounds?

For Semax: BDNF/NGF ELISA from hippocampal tissue; Morris water maze and Y-maze for spatial memory; immunohistochemistry for Arc (activity-regulated cytoskeleton-associated protein) expression. For Selank: GABA receptor expression via western blot; anxiety phenotyping via elevated plus maze (EPM) and light/dark box; IL-6, TNF-α, and IFN-γ measurement for immunomodulatory effects. For Dihexa: dendritic spine density imaging (Golgi staining); c-Met phosphorylation assay; long-term potentiation (LTP) recording in hippocampal slice preparations. For P21: STAT3 and ERK1/2 phosphorylation as direct CNTF pathway readouts; neural progenitor proliferation via BrdU/EdU labeling.

Further Reading:

• •Mitochondrial-Derived Peptides Compared: Humanin vs MOTS-c vs SS-31 in Aging and Cytoprotection Research
• •GHRH Analogs Compared: Sermorelin vs CJC-1295 vs CJC-1295 DAC vs Tesamorelin (2026 Research Guide)
• •GHRPs Compared: GHRP-2 vs GHRP-6 vs Ipamorelin vs Hexarelin — A Complete Research Guide (2026)
• •Best Peptides for Weight Loss Research: GLP-1 Agonists Compared (2026)
• •Peptide Stack Builder
• •Dosage Chart

---

Live Research Pricing: Semax, Selank & P21 (August 2026)

Peptides.SO tracks 151 active listings for Semax, 145 for Selank, and 6 for P21 across verified research suppliers as of August 2026. All three nootropic peptides are available for research procurement, with price variation reflecting vial size differences and supplier tier.

Semax — Current Price Benchmarks

Source: Peptides.SO listings database, August 2026. 151 total Semax listings tracked. See live pricing at Semax compound page.

Selank — Current Price Benchmarks

Source: Peptides.SO listings database, August 2026. 145 total Selank listings tracked. See live pricing at Selank compound page.

P21 — Current Price Benchmarks

Source: Peptides.SO listings database, August 2026. 6 total P21 listings tracked — limited availability relative to Semax and Selank reflects P21's more specialized research niche. See live pricing at P21 compound page.

Market context: Semax and Selank are among the most widely sourced nootropic peptides in the research market, each with 100+ supplier listings. P21 remains a niche compound. Dihexa is not currently tracked in the Peptides.SO database as a mass-market research product — researchers sourcing it should apply particularly careful COA evaluation given limited supplier competition.

Compound Pages — Live Cross-Supplier Pricing

• •Semax on Peptides.SO — 151+ listings, $1.33–$5,825/mg (range includes bulk and trace quantities)
• •Selank on Peptides.SO — 145+ listings, $1.83–$470/mg
• •P21 on Peptides.SO — 6 listings, $3.14–$116/mg

Use the Peptides.SO Reconstitution Calculator to plan research volumes based on available vial sizes and target concentrations.

---

For research use only. Semax, Selank, Dihexa, and P21 are investigational peptides not approved for human administration. All data presented for scientific and educational reference.

---

Neuroprotective Peptides: Live Supplier Market (2026-09-04)

Comparative availability for cognitive and stress-resilience research:

Market insight: Semax and Selank have the broadest supplier bases, reflecting decades of Russian research and adoption into international markets. Dihexa and P-21 are more specialized but increasingly available as Western interest in neuroprotection grows.

---

Choosing a Neuroprotective Peptide: Sourcing & Research Design

Q1: Should I choose Semax, Selank, Dihexa, or P-21 for my neuroprotection study?

A: Depends on your hypothesis:

• •Semax: Broad neuroprotection + memory enhancement; most research volume; easiest sourcing
• •Selank: Anxiety/stress-induced dysregulation; anxiolytic focus
• •Dihexa: Synaptogenesis via HGF pathway; strong CNS penetration
• •P-21: Stress-induced neurodegeneration; targeted acute protection

See Neuroprotective Peptides Compared for detailed pharmacology.

Q2: Why do Semax and Selank have more suppliers than Dihexa and P-21?

A: Semax/Selank are Soviet-era discoveries (1990s); decades of research; approved for clinical use in Russia; established manufacturing. Dihexa and P-21 are newer Western compounds; smaller research volume; fewer suppliers. For newer compounds, expect limited sourcing options initially.

Q3: Can I combine neuroprotective peptides in a single study?

A: Yes. Semax + Selank + Dihexa is an active area; targeting multiple neuroprotective pathways (broad + anxiety + synaptogenesis). No known antagonism at typical research doses. Verify dose compatibility and molar ratios in your model system.

Q4: What dose ranges should I use for each neuroprotective peptide?

A:

• •Semax: 0.1–1 mg/kg intranasal or systemic
• •Selank: 0.1–2 mg/kg; anxiolytic threshold ~0.25 mg/kg
• •Dihexa: 1–10 mg/kg; intranasal for brain penetration
• •P-21: 1–10 mg/kg; acute dosing (stress model-dependent)

Literature varies significantly. Start with published protocols for your specific model.